5-methylcytosine (5-mC) is formed from the DNA methylation of the 5-carbon found on the cytosine ring. A 5-methylcytosine monoclonal antibody is a useful tool in identifying and discriminating between the unmodified cytosine base (C) and the methylated cytosine base (5-mC) as part of DNA methylation studies. DNA methylation plays an important role in the repression of transcription in the genome. When present in promoter regions, 5-mC is associated with stable transcriptional silencing which results in inactivation of gene function, thereby having an important role in tumorigenesis.
5-methylcytosine (5-mC) is formed from the DNA methylation of the 5-carbon found on the cytosine ring. A 5-methylcytosine monoclonal antibody is a useful tool in identifying and discriminating between the unmodified cytosine base (C) and the methylated cytosine base (5-mC) as part of DNA methylation studies. DNA methylation plays an important role in the repression of transcription in the genome. When present in promoter regions, 5-mC is associated with stable transcriptional silencing which results in inactivation of gene function, thereby having an important role in tumorigenesis.
5-methylcytosine (5-mC) is formed from the DNA methylation of the 5-carbon found on the cytosine ring. A 5-methylcytosine monoclonal antibody is a useful tool in identifying and discriminating between the unmodified cytosine base (C) and the methylated cytosine base (5-mC) as part of DNA methylation studies. DNA methylation plays an important role in the repression of transcription in the genome. When present in promoter regions, 5-mC is associated with stable transcriptional silencing which results in inactivation of gene function, thereby having an important role in tumorigenesis.
5-methylcytosine (5-mC) is formed from the DNA methylation of the 5-carbon found on the cytosine ring. A 5-methylcytosine monoclonal antibody is a useful tool in identifying and discriminating between the unmodified cytosine base (C) and the methylated cytosine base (5-mC) as part of DNA methylation studies. DNA methylation plays an important role in the repression of transcription in the genome. When present in promoter regions, 5-mC is associated with stable transcriptional silencing which results in inactivation of gene function, thereby having an important role in tumorigenesis.
Actin is part of the cytoskeletal system of every cell type. It can be classified based on isoelectric points as alpha, beta, and gamma. Muscle Specific Actin includes those of the alpha and gamma isotypes. Skeletal, smooth, and cardiac muscle cells will all stain positively with Anti-Muscle Specific Actin, but mesenchymal cells, not including myoepithelium, will stain negatively. Normal and neoplastic non-muscle cells, including vascular endothelial and connective tissues, carcinomas, melanomas, and lymphomas, will also be negative for muscle specific actin. The use of Anti-Muscle Specific Actin in concert with Anti-Smooth Muscle Actin can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC505
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skeletal Muscle
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Actin is part of the cytoskeletal system of every cell type. It can be classified based on isoelectric points as alpha, beta, and gamma. Muscle Specific Actin includes those of the alpha and gamma isotypes. Skeletal, smooth, and cardiac muscle cells will all stain positively with Anti-Muscle Specific Actin, but mesenchymal cells, not including myoepithelium, will stain negatively. Normal and neoplastic non-muscle cells, including vascular endothelial and connective tissues, carcinomas, melanomas, and lymphomas, will also be negative for muscle specific actin. The use of Anti-Muscle Specific Actin in concert with Anti-Smooth Muscle Actin can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC505
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skeletal Muscle
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Actin is part of the cytoskeletal system of every cell type. It can be classified based on isoelectric points as alpha, beta, and gamma. Muscle Specific Actin includes those of the alpha and gamma isotypes. Skeletal, smooth, and cardiac muscle cells will all stain positively with Anti-Muscle Specific Actin, but mesenchymal cells, not including myoepithelium, will stain negatively. Normal and neoplastic non-muscle cells, including vascular endothelial and connective tissues, carcinomas, melanomas, and lymphomas, will also be negative for muscle specific actin. The use of Anti-Muscle Specific Actin in concert with Anti-Smooth Muscle Actin can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Actin is part of the cytoskeletal system of every cell type. It can be classified based on isoelectric points as alpha, beta, and gamma. Muscle Specific Actin includes those of the alpha and gamma isotypes. Skeletal, smooth, and cardiac muscle cells will all stain positively with Anti-Muscle Specific Actin, but mesenchymal cells, not including myoepithelium, will stain negatively. Normal and neoplastic non-muscle cells, including vascular endothelial and connective tissues, carcinomas, melanomas, and lymphomas, will also be negative for muscle specific actin. The use of Anti-Muscle Specific Actin in concert with Anti-Smooth Muscle Actin can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC505
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skeletal Muscle
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Actin is part of the cytoskeletal system of all cell types. Smooth muscle actin is found in myofibroblasts and myoepithelium, but not in cardiac or skeletal muscles. Labeling of smooth muscle actin in concert with muscle specific actin staining can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle-specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Actin is part of the cytoskeletal system of all cell types. Smooth muscle actin is found in myofibroblasts and myoepithelium, but not in cardiac or skeletal muscles. Labeling of smooth muscle actin in concert with muscle specific actin staining can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle-specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Actin is part of the cytoskeletal system of all cell types. Smooth muscle actin is found in myofibroblasts and myoepithelium, but not in cardiac or skeletal muscles. Labeling of smooth muscle actin in concert with muscle specific actin staining can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle-specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Actin is part of the cytoskeletal system of all cell types. Smooth muscle actin is found in myofibroblasts and myoepithelium, but not in cardiac or skeletal muscles. Labeling of smooth muscle actin in concert with muscle specific actin staining can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle-specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Actin is part of the cytoskeletal system of all cell types. Smooth muscle actin is found in myofibroblasts and myoepithelium, but not in cardiac or skeletal muscles. Labeling of smooth muscle actin in concert with muscle specific actin staining can allow for differentiation between rhabdomyosarcoma and leiomyosarcoma, as muscle-specific actin is found in rhabdomyoblasts, while smooth muscle actin is found in leiomyosarcomas.
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) is an enzyme of the aldo-keto reductase superfamily, and catalyzes the reduction of aliphatic and aromatic aldehydes. AKR1B10 is commonly expressed in adrenal glands, the small intestine, and colon tissues. AKR1B10 staining is useful in the recognition of liver carcinogenesis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC508
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) is an enzyme of the aldo-keto reductase superfamily, and catalyzes the reduction of aliphatic and aromatic aldehydes. AKR1B10 is commonly expressed in adrenal glands, the small intestine, and colon tissues. AKR1B10 staining is useful in the recognition of liver carcinogenesis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC508
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) is an enzyme of the aldo-keto reductase superfamily, and catalyzes the reduction of aliphatic and aromatic aldehydes. AKR1B10 is commonly expressed in adrenal glands, the small intestine, and colon tissues. AKR1B10 staining is useful in the recognition of liver carcinogenesis.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) is an enzyme of the aldo-keto reductase superfamily, and catalyzes the reduction of aliphatic and aromatic aldehydes. AKR1B10 is commonly expressed in adrenal glands, the small intestine, and colon tissues. AKR1B10 staining is useful in the recognition of liver carcinogenesis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC508
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase which plays a role in brain and nervous system development. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system, such as the neonatal brain and spinal cord. The most common genetic alterations of this gene are chromosomal translocations, which result in multiple ALK fusion proteins that are involved in tumourigenesis, as in the case of anaplastic large cell lymphoma (ALCL), lung adenocarcinoma, and inflammatory myofibroblastic tumours. Aberrant ALK expression is also found in other tumours such as familial neuroblastoma, non-small cell lung carcinoma (NSCLC), and brain cancers.
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase which plays a role in brain and nervous system development. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system, such as the neonatal brain and spinal cord. The most common genetic alterations of this gene are chromosomal translocations, which result in multiple ALK fusion proteins that are involved in tumourigenesis, as in the case of anaplastic large cell lymphoma (ALCL), lung adenocarcinoma, and inflammatory myofibroblastic tumours. Aberrant ALK expression is also found in other tumours such as familial neuroblastoma, non-small cell lung carcinoma (NSCLC), and brain cancers.
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase which plays a role in brain and nervous system development. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system, such as the neonatal brain and spinal cord. The most common genetic alterations of this gene are chromosomal translocations, which result in multiple ALK fusion proteins that are involved in tumourigenesis, as in the case of anaplastic large cell lymphoma (ALCL), lung adenocarcinoma, and inflammatory myofibroblastic tumours. Aberrant ALK expression is also found in other tumours such as familial neuroblastoma, non-small cell lung carcinoma (NSCLC), and brain cancers.
Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase which plays a role in brain and nervous system development. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system, such as the neonatal brain and spinal cord. The most common genetic alterations of this gene are chromosomal translocations, which result in multiple ALK fusion proteins that are involved in tumourigenesis, as in the case of anaplastic large cell lymphoma (ALCL), lung adenocarcinoma, and inflammatory myofibroblastic tumours. Aberrant ALK expression is also found in other tumours such as familial neuroblastoma, non-small cell lung carcinoma (NSCLC), and brain cancers.
Alpha-Fetoprotein (AFP) is a major plasma glycoprotein seen in hepatocytes of fetal liver and in hepatoma. Elevated levels of AFP in adult serum may be indicative of hepatocellular carcinoma, hepatoid adenocarcinoma, germ cell tumours, or yolk sac tumours. In hepatocellular carcinoma, AFP expression usually indicates malignancy in a hepatocellular nodule and hepatic histogenesis of a malignancy.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC714
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Alpha-Fetoprotein (AFP) is a major plasma glycoprotein seen in hepatocytes of fetal liver and in hepatoma. Elevated levels of AFP in adult serum may be indicative of hepatocellular carcinoma, hepatoid adenocarcinoma, germ cell tumours, or yolk sac tumours. In hepatocellular carcinoma, AFP expression usually indicates malignancy in a hepatocellular nodule and hepatic histogenesis of a malignancy.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC714
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Alpha-Fetoprotein (AFP) is a major plasma glycoprotein seen in hepatocytes of fetal liver and in hepatoma. Elevated levels of AFP in adult serum may be indicative of hepatocellular carcinoma, hepatoid adenocarcinoma, germ cell tumours, or yolk sac tumours. In hepatocellular carcinoma, AFP expression usually indicates malignancy in a hepatocellular nodule and hepatic histogenesis of a malignancy.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Alpha-Fetoprotein (AFP) is a major plasma glycoprotein seen in hepatocytes of fetal liver and in hepatoma. Elevated levels of AFP in adult serum may be indicative of hepatocellular carcinoma, hepatoid adenocarcinoma, germ cell tumours, or yolk sac tumours. In hepatocellular carcinoma, AFP expression usually indicates malignancy in a hepatocellular nodule and hepatic histogenesis of a malignancy.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC714
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Hepatocellular Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Androgen Receptor (AR) is a transcriptional regulator with a broad array of functions. This marker is clinically significant in the understanding of tumour progression and tumour aggressiveness. The detection of AR by immunohistochemical staining is important for diagnosis of all types of prostate carcinoma, including both therapy-responsive and therapy-unresponsive disease states. Co-testing with AR and CK20 is used for differential diagnosis of desmoplastic trichoepithelioma (DTE) [CK20+/AR-], morpheaform basal cell carcinoma (BCC) [CK20-/AR+], and microcystic adnexal carcinoma (MAC) [CK20-/AR-].
Androgen Receptor (AR) is a transcriptional regulator with a broad array of functions. This marker is clinically significant in the understanding of tumour progression and tumour aggressiveness. The detection of AR by immunohistochemical staining is important for diagnosis of all types of prostate carcinoma, including both therapy-responsive and therapy-unresponsive disease states. Co-testing with AR and CK20 is used for differential diagnosis of desmoplastic trichoepithelioma (DTE) [CK20+/AR-], morpheaform basal cell carcinoma (BCC) [CK20-/AR+], and microcystic adnexal carcinoma (MAC) [CK20-/AR-].
Androgen Receptor (AR) is a transcriptional regulator with a broad array of functions. This marker is clinically significant in the understanding of tumour progression and tumour aggressiveness. The detection of AR by immunohistochemical staining is important for diagnosis of all types of prostate carcinoma, including both therapy-responsive and therapy-unresponsive disease states. Co-testing with AR and CK20 is used for differential diagnosis of desmoplastic trichoepithelioma (DTE) [CK20+/AR-], morpheaform basal cell carcinoma (BCC) [CK20-/AR+], and microcystic adnexal carcinoma (MAC) [CK20-/AR-].
Androgen Receptor (AR) is a transcriptional regulator with a broad array of functions. This marker is clinically significant in the understanding of tumour progression and tumour aggressiveness. The detection of AR by immunohistochemical staining is important for diagnosis of all types of prostate carcinoma, including both therapy-responsive and therapy-unresponsive disease states. Co-testing with AR and CK20 is used for differential diagnosis of desmoplastic trichoepithelioma (DTE) [CK20+/AR-], morpheaform basal cell carcinoma (BCC) [CK20-/AR+], and microcystic adnexal carcinoma (MAC) [CK20-/AR-].
Annexin A1 (ANXA1) is a membrane protein that plays a role in innate and adaptive immunity by controlling the biosynthesis of inflammation, prostaglandins, and leukotriene mediators. This target is overexpressed in 97% of all samples from patients with hairy cell leukemia, and is absent in other B-cell lymphomas. High ANXA1 expression is frequently associated with advanced stage esophageal and esophagogastric junction adenocarcinoma, and is also linked to advanced and metastatic disease states.
Annexin A1 (ANXA1) is a membrane protein that plays a role in innate and adaptive immunity by controlling the biosynthesis of inflammation, prostaglandins, and leukotriene mediators. This target is overexpressed in 97% of all samples from patients with hairy cell leukemia, and is absent in other B-cell lymphomas. High ANXA1 expression is frequently associated with advanced stage esophageal and esophagogastric junction adenocarcinoma, and is also linked to advanced and metastatic disease states.
Annexin A1 (ANXA1) is a membrane protein that plays a role in innate and adaptive immunity by controlling the biosynthesis of inflammation, prostaglandins, and leukotriene mediators. This target is overexpressed in 97% of all samples from patients with hairy cell leukemia, and is absent in other B-cell lymphomas. High ANXA1 expression is frequently associated with advanced stage esophageal and esophagogastric junction adenocarcinoma, and is also linked to advanced and metastatic disease states.
Annexin A1 (ANXA1) is a membrane protein that plays a role in innate and adaptive immunity by controlling the biosynthesis of inflammation, prostaglandins, and leukotriene mediators. This target is overexpressed in 97% of all samples from patients with hairy cell leukemia, and is absent in other B-cell lymphomas. High ANXA1 expression is frequently associated with advanced stage esophageal and esophagogastric junction adenocarcinoma, and is also linked to advanced and metastatic disease states.
Arginase-1, encoded by the ARG1 gene, is a cytosolic metalloenzyme expressed predominantly in hepatocytes. Arginase-1 plays a key role in the urea cycle by catalyzing the hydrolysis of arginine to ornithine and urea. Argininemia is an inherited autosomal recessive disorder characterized by a buildup of arginine and ammonia in the blood. Anti-Arginase-1 is highly specific for hepatocytes, and is therefore a sensitive and specific marker of benign and malignant hepatic tumours.
Arginase-1, encoded by the ARG1 gene, is a cytosolic metalloenzyme expressed predominantly in hepatocytes. Arginase-1 plays a key role in the urea cycle by catalyzing the hydrolysis of arginine to ornithine and urea. Argininemia is an inherited autosomal recessive disorder characterized by a buildup of arginine and ammonia in the blood. Anti-Arginase-1 is highly specific for hepatocytes, and is therefore a sensitive and specific marker of benign and malignant hepatic tumours.
Arginase-1, encoded by the ARG1 gene, is a cytosolic metalloenzyme expressed predominantly in hepatocytes. Arginase-1 plays a key role in the urea cycle by catalyzing the hydrolysis of arginine to ornithine and urea. Argininemia is an inherited autosomal recessive disorder characterized by a buildup of arginine and ammonia in the blood. Anti-Arginase-1 is highly specific for hepatocytes, and is therefore a sensitive and specific marker of benign and malignant hepatic tumours.
Arginase-1, encoded by the ARG1 gene, is a cytosolic metalloenzyme expressed predominantly in hepatocytes. Arginase-1 plays a key role in the urea cycle by catalyzing the hydrolysis of arginine to ornithine and urea. Argininemia is an inherited autosomal recessive disorder characterized by a buildup of arginine and ammonia in the blood. Anti-Arginase-1 is highly specific for hepatocytes, and is therefore a sensitive and specific marker of benign and malignant hepatic tumours.
B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC104
Antibody Isotype:
IgG2b
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC104
Antibody Isotype:
IgG2b
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC104
Antibody Isotype:
IgG2b
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
B-Cell Lymphoma 2 (BCL2) is involved in regulation of cell apoptosis by controlling mitochondrial permeability and release of cytochrome c. It also has critical roles in normal cell physiology related to neuronal activity, autophagy, calcium handling, mitochondrial dynamics, and energetics. BCL2 overexpression has been shown to promote cell survival by suppressing apoptosis, and is found to be correlated with poor disease prognosis in breast, prostate, ovarian, endometrial, and colon cancers. In follicular lymphoma, Anti-BCL2 reacts negatively with germinal centers and positively with neoplastic follicles. In lymphoid lesions, BCL2 staining is useful for distinguishing reactive and neoplastic follicular proliferations, and for identifying minimal residual disease in the bone marrow of follicular lymphoma patients. BCL2 is now a useful target of human cancer therapy.
B-Cell Lymphoma 2 (BCL2) is involved in regulation of cell apoptosis by controlling mitochondrial permeability and release of cytochrome c. It also has critical roles in normal cell physiology related to neuronal activity, autophagy, calcium handling, mitochondrial dynamics, and energetics. BCL2 overexpression has been shown to promote cell survival by suppressing apoptosis, and is found to be correlated with poor disease prognosis in breast, prostate, ovarian, endometrial, and colon cancers. In follicular lymphoma, Anti-BCL2 reacts negatively with germinal centers and positively with neoplastic follicles. In lymphoid lesions, BCL2 staining is useful for distinguishing reactive and neoplastic follicular proliferations, and for identifying minimal residual disease in the bone marrow of follicular lymphoma patients. BCL2 is now a useful target of human cancer therapy.
B-Cell Lymphoma 2 (BCL2) is involved in regulation of cell apoptosis by controlling mitochondrial permeability and release of cytochrome c. It also has critical roles in normal cell physiology related to neuronal activity, autophagy, calcium handling, mitochondrial dynamics, and energetics. BCL2 overexpression has been shown to promote cell survival by suppressing apoptosis, and is found to be correlated with poor disease prognosis in breast, prostate, ovarian, endometrial, and colon cancers. In follicular lymphoma, Anti-BCL2 reacts negatively with germinal centers and positively with neoplastic follicles. In lymphoid lesions, BCL2 staining is useful for distinguishing reactive and neoplastic follicular proliferations, and for identifying minimal residual disease in the bone marrow of follicular lymphoma patients. BCL2 is now a useful target of human cancer therapy.
B-Cell Lymphoma 2 (BCL2) is involved in regulation of cell apoptosis by controlling mitochondrial permeability and release of cytochrome c. It also has critical roles in normal cell physiology related to neuronal activity, autophagy, calcium handling, mitochondrial dynamics, and energetics. BCL2 overexpression has been shown to promote cell survival by suppressing apoptosis, and is found to be correlated with poor disease prognosis in breast, prostate, ovarian, endometrial, and colon cancers. In follicular lymphoma, Anti-BCL2 reacts negatively with germinal centers and positively with neoplastic follicles. In lymphoid lesions, BCL2 staining is useful for distinguishing reactive and neoplastic follicular proliferations, and for identifying minimal residual disease in the bone marrow of follicular lymphoma patients. BCL2 is now a useful target of human cancer therapy.
B-Cell Lymphoma 6 (BCL6) is a zinc finger transcription factor. BCL6 expression is seen in follicular lymphomas, Burkitt's lymphoma, angioimmunoblastic T-cell lymphoma, and nodular lymphocyte-predominant Hodgkin's lymphoma. Together with BCL2, BCL6 is often used to distinguish neoplastic follicles from those in benign hyperplasia, and to aid in the classification of mantle cell lymphomas and nodular lymphocyte-predominant Hodgkin's lymphoma.
B-Cell Lymphoma 6 (BCL6) is a zinc finger transcription factor. BCL6 expression is seen in follicular lymphomas, Burkitt's lymphoma, angioimmunoblastic T-cell lymphoma, and nodular lymphocyte-predominant Hodgkin's lymphoma. Together with BCL2, BCL6 is often used to distinguish neoplastic follicles from those in benign hyperplasia, and to aid in the classification of mantle cell lymphomas and nodular lymphocyte-predominant Hodgkin's lymphoma.
B-Cell Lymphoma 6 (BCL6) is a zinc finger transcription factor. BCL6 expression is seen in follicular lymphomas, Burkitt's lymphoma, angioimmunoblastic T-cell lymphoma, and nodular lymphocyte-predominant Hodgkin's lymphoma. Together with BCL2, BCL6 is often used to distinguish neoplastic follicles from those in benign hyperplasia, and to aid in the classification of mantle cell lymphomas and nodular lymphocyte-predominant Hodgkin's lymphoma.
B-Cell Lymphoma 6 (BCL6) is a zinc finger transcription factor. BCL6 expression is seen in follicular lymphomas, Burkitt's lymphoma, angioimmunoblastic T-cell lymphoma, and nodular lymphocyte-predominant Hodgkin's lymphoma. Together with BCL2, BCL6 is often used to distinguish neoplastic follicles from those in benign hyperplasia, and to aid in the classification of mantle cell lymphomas and nodular lymphocyte-predominant Hodgkin's lymphoma.
β-Catenin is a cytoplasmic protein with a dual role in cell-cell adhesion and gene expression. It is normally present in the submembranous regions of the cell, and nuclear accumulation of β-Catenin has been found to occur as a result of gene mutations. This accumulation is useful in identifying desmoid tumours (fibromatosis) in the abdomen and breast, and is therefore useful in differentiating other cell neoplasms in these regions.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC516
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Fibromatosis of Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
β-Catenin is a cytoplasmic protein with a dual role in cell-cell adhesion and gene expression. It is normally present in the submembranous regions of the cell, and nuclear accumulation of β-Catenin has been found to occur as a result of gene mutations. This accumulation is useful in identifying desmoid tumours (fibromatosis) in the abdomen and breast, and is therefore useful in differentiating other cell neoplasms in these regions.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC516
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Fibromatosis of Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
β-Catenin is a cytoplasmic protein with a dual role in cell-cell adhesion and gene expression. It is normally present in the submembranous regions of the cell, and nuclear accumulation of β-Catenin has been found to occur as a result of gene mutations. This accumulation is useful in identifying desmoid tumours (fibromatosis) in the abdomen and breast, and is therefore useful in differentiating other cell neoplasms in these regions.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
β-Catenin is a cytoplasmic protein with a dual role in cell-cell adhesion and gene expression. It is normally present in the submembranous regions of the cell, and nuclear accumulation of β-Catenin has been found to occur as a result of gene mutations. This accumulation is useful in identifying desmoid tumours (fibromatosis) in the abdomen and breast, and is therefore useful in differentiating other cell neoplasms in these regions.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC516
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Fibromatosis of Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
BG8 Lewis<sup>y</sup>, also known as Lewis<sup>y</sup> Blood Antigen or simply BG8, is a blood group antigen that has been identified in many studies as a potential marker for differentiation between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). It has been reported that sensitivity of non-mesothelial antigens for adenocarcinoma is organ-dependent. When attempting to differentiate epithelioid mesothelioma from adenocarcinoma, BG8 Lewis<sup>y</sup> performed at a sensitivity of 98% in the breast cancer group, and 100% in the lung cancer group.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC517
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
BG8 Lewis<sup>y</sup>, also known as Lewis<sup>y</sup> Blood Antigen or simply BG8, is a blood group antigen that has been identified in many studies as a potential marker for differentiation between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). It has been reported that sensitivity of non-mesothelial antigens for adenocarcinoma is organ-dependent. When attempting to differentiate epithelioid mesothelioma from adenocarcinoma, BG8 Lewis<sup>y</sup> performed at a sensitivity of 98% in the breast cancer group, and 100% in the lung cancer group.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC517
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
BG8 Lewis<sup>y</sup>, also known as Lewis<sup>y</sup> Blood Antigen or simply BG8, is a blood group antigen that has been identified in many studies as a potential marker for differentiation between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). It has been reported that sensitivity of non-mesothelial antigens for adenocarcinoma is organ-dependent. When attempting to differentiate epithelioid mesothelioma from adenocarcinoma, BG8 Lewis<sup>y</sup> performed at a sensitivity of 98% in the breast cancer group, and 100% in the lung cancer group.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
BG8 Lewis<sup>y</sup>, also known as Lewis<sup>y</sup> Blood Antigen or simply BG8, is a blood group antigen that has been identified in many studies as a potential marker for differentiation between pulmonary adenocarcinoma (PACA) and epithelioid mesothelioma (EM). It has been reported that sensitivity of non-mesothelial antigens for adenocarcinoma is organ-dependent. When attempting to differentiate epithelioid mesothelioma from adenocarcinoma, BG8 Lewis<sup>y</sup> performed at a sensitivity of 98% in the breast cancer group, and 100% in the lung cancer group.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC517
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Serine/Threonine-Protein Kinase B-Raf (BRAF) is a cytoplasmic serine-threonine kinase of the RAF family, which mediates downstream cellular responses to growth signals through the mitogen-activated protein kinase (MAPK) signaling pathway. Oncogenic mutations in the BRAF gene, 80% of which are a single V600E substitution within the kinase domain, constitutively activate the MAPK signaling pathway and result in increased cell proliferation and apoptosis resistance. The V600E mutation is observed in colorectal cancer, non-Hodgkin's lymphoma, papillary thyroid carcinoma, malignant melanoma, non-small-cell lung carcinoma, and lung adenocarcinoma. BRAF V600E is therefore an important immunohistochemical marker for tumour diagnosis and prognosis.
Serine/Threonine-Protein Kinase B-Raf (BRAF) is a cytoplasmic serine-threonine kinase of the RAF family, which mediates downstream cellular responses to growth signals through the mitogen-activated protein kinase (MAPK) signaling pathway. Oncogenic mutations in the BRAF gene, 80% of which are a single V600E substitution within the kinase domain, constitutively activate the MAPK signaling pathway and result in increased cell proliferation and apoptosis resistance. The V600E mutation is observed in colorectal cancer, non-Hodgkin's lymphoma, papillary thyroid carcinoma, malignant melanoma, non-small-cell lung carcinoma, and lung adenocarcinoma. BRAF V600E is therefore an important immunohistochemical marker for tumour diagnosis and prognosis.
Serine/Threonine-Protein Kinase B-Raf (BRAF) is a cytoplasmic serine-threonine kinase of the RAF family, which mediates downstream cellular responses to growth signals through the mitogen-activated protein kinase (MAPK) signaling pathway. Oncogenic mutations in the BRAF gene, 80% of which are a single V600E substitution within the kinase domain, constitutively activate the MAPK signaling pathway and result in increased cell proliferation and apoptosis resistance. The V600E mutation is observed in colorectal cancer, non-Hodgkin's lymphoma, papillary thyroid carcinoma, malignant melanoma, non-small-cell lung carcinoma, and lung adenocarcinoma. BRAF V600E is therefore an important immunohistochemical marker for tumour diagnosis and prognosis.
Serine/Threonine-Protein Kinase B-Raf (BRAF) is a cytoplasmic serine-threonine kinase of the RAF family, which mediates downstream cellular responses to growth signals through the mitogen-activated protein kinase (MAPK) signaling pathway. Oncogenic mutations in the BRAF gene, 80% of which are a single V600E substitution within the kinase domain, constitutively activate the MAPK signaling pathway and result in increased cell proliferation and apoptosis resistance. The V600E mutation is observed in colorectal cancer, non-Hodgkin's lymphoma, papillary thyroid carcinoma, malignant melanoma, non-small-cell lung carcinoma, and lung adenocarcinoma. BRAF V600E is therefore an important immunohistochemical marker for tumour diagnosis and prognosis.
Serine/Threonine-Protein Kinase B-Raf (BRAF) is a cytoplasmic serine-threonine kinase of the RAF family, which mediates downstream cellular responses to growth signals through the mitogen-activated protein kinase (MAPK) signaling pathway. Oncogenic mutations in the BRAF gene, 80% of which are a single V600E substitution within the kinase domain, constitutively activate the MAPK signaling pathway and result in increased cell proliferation and apoptosis resistance. The V600E mutation is observed in colorectal cancer, non-Hodgkin's lymphoma, papillary thyroid carcinoma, malignant melanoma, non-small-cell lung carcinoma, and lung adenocarcinoma. BRAF V600E is therefore an important immunohistochemical marker for tumour diagnosis and prognosis.
Bile Salt Export Pump (BSEP) is a member of the ATP-binding cassette (ABC) transporters, and mediates the transport of bile acid, taurocholate, and other cholate conjugates across the hepatocyte canalicular membrane into the canaliculus. BSEP is associated with progressive familial intrahepatic cholestasis type 2 (PFIC2) and benign recurrent intrahepatic cholestasis type 2 (BRIC2). PFIC2 caused by mutations in the BSEP gene increases the risk of hepatocellular carcinoma in early life.
Bile Salt Export Pump (BSEP) is a member of the ATP-binding cassette (ABC) transporters, and mediates the transport of bile acid, taurocholate, and other cholate conjugates across the hepatocyte canalicular membrane into the canaliculus. BSEP is associated with progressive familial intrahepatic cholestasis type 2 (PFIC2) and benign recurrent intrahepatic cholestasis type 2 (BRIC2). PFIC2 caused by mutations in the BSEP gene increases the risk of hepatocellular carcinoma in early life.
Bile Salt Export Pump (BSEP) is a member of the ATP-binding cassette (ABC) transporters, and mediates the transport of bile acid, taurocholate, and other cholate conjugates across the hepatocyte canalicular membrane into the canaliculus. BSEP is associated with progressive familial intrahepatic cholestasis type 2 (PFIC2) and benign recurrent intrahepatic cholestasis type 2 (BRIC2). PFIC2 caused by mutations in the BSEP gene increases the risk of hepatocellular carcinoma in early life.
Bile Salt Export Pump (BSEP) is a member of the ATP-binding cassette (ABC) transporters, and mediates the transport of bile acid, taurocholate, and other cholate conjugates across the hepatocyte canalicular membrane into the canaliculus. BSEP is associated with progressive familial intrahepatic cholestasis type 2 (PFIC2) and benign recurrent intrahepatic cholestasis type 2 (BRIC2). PFIC2 caused by mutations in the BSEP gene increases the risk of hepatocellular carcinoma in early life.
CA-125 is normally found in epithelial cells of Fallopian tube, endometrium and endocervix, pancreas, colon, gall bladder, stomach, kidney, apocrine sweat gland, mammary gland, and mesothelial cell lining of pleura, pericardium, and the peritoneum. Anti-CA-125 reacts positively with ovarian malignancies, cervical carcinoma, seminal vesicle carcinoma, anaplastic lymphoma, and endometrial and bladder adenocarcinoma.
CA-125 is normally found in epithelial cells of Fallopian tube, endometrium and endocervix, pancreas, colon, gall bladder, stomach, kidney, apocrine sweat gland, mammary gland, and mesothelial cell lining of pleura, pericardium, and the peritoneum. Anti-CA-125 reacts positively with ovarian malignancies, cervical carcinoma, seminal vesicle carcinoma, anaplastic lymphoma, and endometrial and bladder adenocarcinoma.
CA-125 is normally found in epithelial cells of Fallopian tube, endometrium and endocervix, pancreas, colon, gall bladder, stomach, kidney, apocrine sweat gland, mammary gland, and mesothelial cell lining of pleura, pericardium, and the peritoneum. Anti-CA-125 reacts positively with ovarian malignancies, cervical carcinoma, seminal vesicle carcinoma, anaplastic lymphoma, and endometrial and bladder adenocarcinoma.
CA-125 is normally found in epithelial cells of Fallopian tube, endometrium and endocervix, pancreas, colon, gall bladder, stomach, kidney, apocrine sweat gland, mammary gland, and mesothelial cell lining of pleura, pericardium, and the peritoneum. Anti-CA-125 reacts positively with ovarian malignancies, cervical carcinoma, seminal vesicle carcinoma, anaplastic lymphoma, and endometrial and bladder adenocarcinoma.
CA 19-9 is a secreted protein that is implicated in various cancers. It is overexpressed in salivary gland mucoepidermoid carcinomas and gastric, pancreatic, and colonic (gastrointestinal) adenocarcinomas, but is not expressed in breast, kidney, and prostate carcinomas. CA 19-9 staining is also implicated in Mirizzi’s Syndrome or other bile duct and liver diseases.
CA 19-9 is a secreted protein that is implicated in various cancers. It is overexpressed in salivary gland mucoepidermoid carcinomas and gastric, pancreatic, and colonic (gastrointestinal) adenocarcinomas, but is not expressed in breast, kidney, and prostate carcinomas. CA 19-9 staining is also implicated in Mirizzi’s Syndrome or other bile duct and liver diseases.
CA 19-9 is a secreted protein that is implicated in various cancers. It is overexpressed in salivary gland mucoepidermoid carcinomas and gastric, pancreatic, and colonic (gastrointestinal) adenocarcinomas, but is not expressed in breast, kidney, and prostate carcinomas. CA 19-9 staining is also implicated in Mirizzi’s Syndrome or other bile duct and liver diseases.
CA 19-9 is a secreted protein that is implicated in various cancers. It is overexpressed in salivary gland mucoepidermoid carcinomas and gastric, pancreatic, and colonic (gastrointestinal) adenocarcinomas, but is not expressed in breast, kidney, and prostate carcinomas. CA 19-9 staining is also implicated in Mirizzi’s Syndrome or other bile duct and liver diseases.
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Caldesmon is a marker for smooth muscle differentiation. Found in smooth muscle and other tissues, caldesmon interacts with Ca<sup>2+</sup>-calmodulin, actin, tropomyosin, myosin, and phospholipids. It inhibits the ATPase activity of myosin in smooth muscle, and mediates Ca<sup>2+</sup>-dependent inhibition of smooth muscle and non-muscle contraction. Caldesmon expression is found in Gastrointestinal Stromal Tumours (GIST), and can be used to differentiate epithelioid mesothelioma from serous papillary carcinoma of the ovary. It is also a specific marker for smooth muscle cells (SMC) and associated neoplasms; therefore, Anti-Caldesmon can be used in the study of the SMC differentiation process as well as the differentiation of other tumours with SMC-like differentiation, including leiomyosarcoma and myofibroblastic tumours.
Caldesmon is a marker for smooth muscle differentiation. Found in smooth muscle and other tissues, caldesmon interacts with Ca<sup>2+</sup>-calmodulin, actin, tropomyosin, myosin, and phospholipids. It inhibits the ATPase activity of myosin in smooth muscle, and mediates Ca<sup>2+</sup>-dependent inhibition of smooth muscle and non-muscle contraction. Caldesmon expression is found in Gastrointestinal Stromal Tumours (GIST), and can be used to differentiate epithelioid mesothelioma from serous papillary carcinoma of the ovary. It is also a specific marker for smooth muscle cells (SMC) and associated neoplasms; therefore, Anti-Caldesmon can be used in the study of the SMC differentiation process as well as the differentiation of other tumours with SMC-like differentiation, including leiomyosarcoma and myofibroblastic tumours.
Caldesmon is a marker for smooth muscle differentiation. Found in smooth muscle and other tissues, caldesmon interacts with Ca<sup>2+</sup>-calmodulin, actin, tropomyosin, myosin, and phospholipids. It inhibits the ATPase activity of myosin in smooth muscle, and mediates Ca<sup>2+</sup>-dependent inhibition of smooth muscle and non-muscle contraction. Caldesmon expression is found in Gastrointestinal Stromal Tumours (GIST), and can be used to differentiate epithelioid mesothelioma from serous papillary carcinoma of the ovary. It is also a specific marker for smooth muscle cells (SMC) and associated neoplasms; therefore, Anti-Caldesmon can be used in the study of the SMC differentiation process as well as the differentiation of other tumours with SMC-like differentiation, including leiomyosarcoma and myofibroblastic tumours.
Caldesmon is a marker for smooth muscle differentiation. Found in smooth muscle and other tissues, caldesmon interacts with Ca<sup>2+</sup>-calmodulin, actin, tropomyosin, myosin, and phospholipids. It inhibits the ATPase activity of myosin in smooth muscle, and mediates Ca<sup>2+</sup>-dependent inhibition of smooth muscle and non-muscle contraction. Caldesmon expression is found in Gastrointestinal Stromal Tumours (GIST), and can be used to differentiate epithelioid mesothelioma from serous papillary carcinoma of the ovary. It is also a specific marker for smooth muscle cells (SMC) and associated neoplasms; therefore, Anti-Caldesmon can be used in the study of the SMC differentiation process as well as the differentiation of other tumours with SMC-like differentiation, including leiomyosarcoma and myofibroblastic tumours.
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calretinin is a calcium-binding protein that functions as a modulator of neuronal excitability and may play a protective role in the survival of nerve cells during disturbances in calcium homeostasis. It is abundantly expressed in subsets of neurons throughout the brain and spinal cord, particularly retina and sensory ganglia, but it is also found in mesothelium, eccrine sweat glands, Sertoli cells, ovarian stromal cells, and adrenal cortical cells. Due to its high sensitivity against mesothelial cells, calretinin is a useful marker in differentiating mesothelioma and metastatic adenocarcinoma to the serous membranes. It is also a diagnostic marker of Hirschsprung's disease and some ovarian and testicular cancers such as Sertoli-Leydig cell tumour, Sertoli cell tumour, Leydig cell tumour, sex cord tumour with annular tubules, and steroid cell tumour.
Calretinin is a calcium-binding protein that functions as a modulator of neuronal excitability and may play a protective role in the survival of nerve cells during disturbances in calcium homeostasis. It is abundantly expressed in subsets of neurons throughout the brain and spinal cord, particularly retina and sensory ganglia, but it is also found in mesothelium, eccrine sweat glands, Sertoli cells, ovarian stromal cells, and adrenal cortical cells. Due to its high sensitivity against mesothelial cells, calretinin is a useful marker in differentiating mesothelioma and metastatic adenocarcinoma to the serous membranes. It is also a diagnostic marker of Hirschsprung's disease and some ovarian and testicular cancers such as Sertoli-Leydig cell tumour, Sertoli cell tumour, Leydig cell tumour, sex cord tumour with annular tubules, and steroid cell tumour.
Calretinin is a calcium-binding protein that functions as a modulator of neuronal excitability and may play a protective role in the survival of nerve cells during disturbances in calcium homeostasis. It is abundantly expressed in subsets of neurons throughout the brain and spinal cord, particularly retina and sensory ganglia, but it is also found in mesothelium, eccrine sweat glands, Sertoli cells, ovarian stromal cells, and adrenal cortical cells. Due to its high sensitivity against mesothelial cells, calretinin is a useful marker in differentiating mesothelioma and metastatic adenocarcinoma to the serous membranes. It is also a diagnostic marker of Hirschsprung's disease and some ovarian and testicular cancers such as Sertoli-Leydig cell tumour, Sertoli cell tumour, Leydig cell tumour, sex cord tumour with annular tubules, and steroid cell tumour.
Calretinin is a calcium-binding protein that functions as a modulator of neuronal excitability and may play a protective role in the survival of nerve cells during disturbances in calcium homeostasis. It is abundantly expressed in subsets of neurons throughout the brain and spinal cord, particularly retina and sensory ganglia, but it is also found in mesothelium, eccrine sweat glands, Sertoli cells, ovarian stromal cells, and adrenal cortical cells. Due to its high sensitivity against mesothelial cells, calretinin is a useful marker in differentiating mesothelioma and metastatic adenocarcinoma to the serous membranes. It is also a diagnostic marker of Hirschsprung's disease and some ovarian and testicular cancers such as Sertoli-Leydig cell tumour, Sertoli cell tumour, Leydig cell tumour, sex cord tumour with annular tubules, and steroid cell tumour.
Cluster of Differentiation 10 (CD10) is a cell surface metalloendopeptidase that cleaves and inactivates several peptide hormones including glucagon, enkephalins, and oxytocin. Also known as Common Acute Lymphoblastic Leukemia Antigen (CALLA), it is an important cell surface marker in the diagnosis of human ALL (Acute Lymphocytic Leukemia), and is found positive in precursor B lymphoblastic leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, Burkitt's lymphoma, and follicular germinal center lymphoma. CD10 expression has also been reported in a variety of non-hematolymphoid tissues, particularly of the kidney. It is a useful aid in the diagnosis of various malignant tumours such as renal cell carcinoma, endometrial stromal sarcoma, and hepatocellular carcinoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC525
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Kidney, Lymph Node, Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 10 (CD10) is a cell surface metalloendopeptidase that cleaves and inactivates several peptide hormones including glucagon, enkephalins, and oxytocin. Also known as Common Acute Lymphoblastic Leukemia Antigen (CALLA), it is an important cell surface marker in the diagnosis of human ALL (Acute Lymphocytic Leukemia), and is found positive in precursor B lymphoblastic leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, Burkitt's lymphoma, and follicular germinal center lymphoma. CD10 expression has also been reported in a variety of non-hematolymphoid tissues, particularly of the kidney. It is a useful aid in the diagnosis of various malignant tumours such as renal cell carcinoma, endometrial stromal sarcoma, and hepatocellular carcinoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC525
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Kidney, Lymph Node, Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 10 (CD10) is a cell surface metalloendopeptidase that cleaves and inactivates several peptide hormones including glucagon, enkephalins, and oxytocin. Also known as Common Acute Lymphoblastic Leukemia Antigen (CALLA), it is an important cell surface marker in the diagnosis of human ALL (Acute Lymphocytic Leukemia), and is found positive in precursor B lymphoblastic leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, Burkitt's lymphoma, and follicular germinal center lymphoma. CD10 expression has also been reported in a variety of non-hematolymphoid tissues, particularly of the kidney. It is a useful aid in the diagnosis of various malignant tumours such as renal cell carcinoma, endometrial stromal sarcoma, and hepatocellular carcinoma.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 10 (CD10) is a cell surface metalloendopeptidase that cleaves and inactivates several peptide hormones including glucagon, enkephalins, and oxytocin. Also known as Common Acute Lymphoblastic Leukemia Antigen (CALLA), it is an important cell surface marker in the diagnosis of human ALL (Acute Lymphocytic Leukemia), and is found positive in precursor B lymphoblastic leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, Burkitt's lymphoma, and follicular germinal center lymphoma. CD10 expression has also been reported in a variety of non-hematolymphoid tissues, particularly of the kidney. It is a useful aid in the diagnosis of various malignant tumours such as renal cell carcinoma, endometrial stromal sarcoma, and hepatocellular carcinoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC525
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Kidney, Lymph Node, Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD117 or Proto-oncogene c-Kit (c-Kit) is a member of the Tyrosine Kinase Receptor (TKR) family, and is an important cell surface marker found on hematopoietic stem cells, melanocytes, mast cells, Cajal cells, germ cells, basal cells of skin, and mammary ductal epithelia. It is considered an important marker in the diagnosis and classification of Gastrointestinal Stromal Tumours (GISTs), mast cell diseases, Acute Myeloid Leukemia (AML), Small Cell Lung Carcinoma (SCLC), and Ewing's sarcoma.
CD117 or Proto-oncogene c-Kit (c-Kit) is a member of the Tyrosine Kinase Receptor (TKR) family, and is an important cell surface marker found on hematopoietic stem cells, melanocytes, mast cells, Cajal cells, germ cells, basal cells of skin, and mammary ductal epithelia. It is considered an important marker in the diagnosis and classification of Gastrointestinal Stromal Tumours (GISTs), mast cell diseases, Acute Myeloid Leukemia (AML), Small Cell Lung Carcinoma (SCLC), and Ewing's sarcoma.
CD117 or Proto-oncogene c-Kit (c-Kit) is a member of the Tyrosine Kinase Receptor (TKR) family, and is an important cell surface marker found on hematopoietic stem cells, melanocytes, mast cells, Cajal cells, germ cells, basal cells of skin, and mammary ductal epithelia. It is considered an important marker in the diagnosis and classification of Gastrointestinal Stromal Tumours (GISTs), mast cell diseases, Acute Myeloid Leukemia (AML), Small Cell Lung Carcinoma (SCLC), and Ewing's sarcoma.
CD117 or Proto-oncogene c-Kit (c-Kit) is a member of the Tyrosine Kinase Receptor (TKR) family, and is an important cell surface marker found on hematopoietic stem cells, melanocytes, mast cells, Cajal cells, germ cells, basal cells of skin, and mammary ductal epithelia. It is considered an important marker in the diagnosis and classification of Gastrointestinal Stromal Tumours (GISTs), mast cell diseases, Acute Myeloid Leukemia (AML), Small Cell Lung Carcinoma (SCLC), and Ewing's sarcoma.
Cluster of Differentiation 138 (CD138), also known as Syndecan-1, is a trans- membrane glycoprotein present on the surface of B-cells during late stage differentiation. Anti-CD138 is used to differentiate marginal zone lymphoma from lymphoplasmacytic lymphoma. ALK+ Large B-Cell Lymphoma (LBCL) commonly stains positively for CD138, but not for CD20 and CD79a. Anti-CD138 reacts positively with HHV8-associated primary effusion lymphoma that lacks B-cell markers. CD138 is also a useful marker for identifying and enumerating benign, reactive, or malignant plasma cells from the bone marrow biopsy samples.
Cluster of Differentiation 138 (CD138), also known as Syndecan-1, is a trans- membrane glycoprotein present on the surface of B-cells during late stage differentiation. Anti-CD138 is used to differentiate marginal zone lymphoma from lymphoplasmacytic lymphoma. ALK+ Large B-Cell Lymphoma (LBCL) commonly stains positively for CD138, but not for CD20 and CD79a. Anti-CD138 reacts positively with HHV8-associated primary effusion lymphoma that lacks B-cell markers. CD138 is also a useful marker for identifying and enumerating benign, reactive, or malignant plasma cells from the bone marrow biopsy samples.
Cluster of Differentiation 138 (CD138), also known as Syndecan-1, is a trans- membrane glycoprotein present on the surface of B-cells during late stage differentiation. Anti-CD138 is used to differentiate marginal zone lymphoma from lymphoplasmacytic lymphoma. ALK+ Large B-Cell Lymphoma (LBCL) commonly stains positively for CD138, but not for CD20 and CD79a. Anti-CD138 reacts positively with HHV8-associated primary effusion lymphoma that lacks B-cell markers. CD138 is also a useful marker for identifying and enumerating benign, reactive, or malignant plasma cells from the bone marrow biopsy samples.
Cluster of Differentiation 138 (CD138), also known as Syndecan-1, is a trans- membrane glycoprotein present on the surface of B-cells during late stage differentiation. Anti-CD138 is used to differentiate marginal zone lymphoma from lymphoplasmacytic lymphoma. ALK+ Large B-Cell Lymphoma (LBCL) commonly stains positively for CD138, but not for CD20 and CD79a. Anti-CD138 reacts positively with HHV8-associated primary effusion lymphoma that lacks B-cell markers. CD138 is also a useful marker for identifying and enumerating benign, reactive, or malignant plasma cells from the bone marrow biopsy samples.
Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt's lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC013
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Liver
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt's lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC013
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Liver
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt's lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt's lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC013
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Liver
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 15 (CD15), also known as Leu-M1, is a carbohydrate adhesion molecule. Positive staining for CD15 and negative staining for leukocyte common antigen or other B- or T-cell lineage markers helps recognize Reed Sternberg cells (RSC) in classic Hodgkin's lymphoma, and distinguishes it from Hodgkin-like neoplasms. CD15 does not stain mesotheliomas and is therefore most useful for distinguishing epithelial mesothelioma from adenocarcinoma.
Cluster of Differentiation 15 (CD15), also known as Leu-M1, is a carbohydrate adhesion molecule. Positive staining for CD15 and negative staining for leukocyte common antigen or other B- or T-cell lineage markers helps recognize Reed Sternberg cells (RSC) in classic Hodgkin's lymphoma, and distinguishes it from Hodgkin-like neoplasms. CD15 does not stain mesotheliomas and is therefore most useful for distinguishing epithelial mesothelioma from adenocarcinoma.
Cluster of Differentiation 15 (CD15), also known as Leu-M1, is a carbohydrate adhesion molecule. Positive staining for CD15 and negative staining for leukocyte common antigen or other B- or T-cell lineage markers helps recognize Reed Sternberg cells (RSC) in classic Hodgkin's lymphoma, and distinguishes it from Hodgkin-like neoplasms. CD15 does not stain mesotheliomas and is therefore most useful for distinguishing epithelial mesothelioma from adenocarcinoma.
Cluster of Differentiation 15 (CD15), also known as Leu-M1, is a carbohydrate adhesion molecule. Positive staining for CD15 and negative staining for leukocyte common antigen or other B- or T-cell lineage markers helps recognize Reed Sternberg cells (RSC) in classic Hodgkin's lymphoma, and distinguishes it from Hodgkin-like neoplasms. CD15 does not stain mesotheliomas and is therefore most useful for distinguishing epithelial mesothelioma from adenocarcinoma.
Cluster of Differentiation 163 (CD163) is a receptor found exclusively on the surface of monocytes and macrophages. The solubilized form in plasma is upregulated in inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and Gaucher’s disease, which supports recent studies that have found IL-10, glucocorticoids, and other inflammatory modulators to upregulate CD163 expression. CD163 staining is useful for differentiating synovial intimal fibroblasts from synovial macrophages in rheumatoid arthritis. Overexpression of CD163 is also present in patients with myelomonocytic leukemia dealing with microbial infections. CD163 expression is found in leukemias with monocytic differentiation and synovial-type giant cell tumours of the vertebral column.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC163
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Inflamed Tissue
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 163 (CD163) is a receptor found exclusively on the surface of monocytes and macrophages. The solubilized form in plasma is upregulated in inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and Gaucher’s disease, which supports recent studies that have found IL-10, glucocorticoids, and other inflammatory modulators to upregulate CD163 expression. CD163 staining is useful for differentiating synovial intimal fibroblasts from synovial macrophages in rheumatoid arthritis. Overexpression of CD163 is also present in patients with myelomonocytic leukemia dealing with microbial infections. CD163 expression is found in leukemias with monocytic differentiation and synovial-type giant cell tumours of the vertebral column.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC163
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Inflamed Tissue
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 163 (CD163) is a receptor found exclusively on the surface of monocytes and macrophages. The solubilized form in plasma is upregulated in inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and Gaucher’s disease, which supports recent studies that have found IL-10, glucocorticoids, and other inflammatory modulators to upregulate CD163 expression. CD163 staining is useful for differentiating synovial intimal fibroblasts from synovial macrophages in rheumatoid arthritis. Overexpression of CD163 is also present in patients with myelomonocytic leukemia dealing with microbial infections. CD163 expression is found in leukemias with monocytic differentiation and synovial-type giant cell tumours of the vertebral column.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 163 (CD163) is a receptor found exclusively on the surface of monocytes and macrophages. The solubilized form in plasma is upregulated in inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and Gaucher’s disease, which supports recent studies that have found IL-10, glucocorticoids, and other inflammatory modulators to upregulate CD163 expression. CD163 staining is useful for differentiating synovial intimal fibroblasts from synovial macrophages in rheumatoid arthritis. Overexpression of CD163 is also present in patients with myelomonocytic leukemia dealing with microbial infections. CD163 expression is found in leukemias with monocytic differentiation and synovial-type giant cell tumours of the vertebral column.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC163
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Inflamed Tissue
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 19 (CD19) is a surface receptor found on follicular dendritic cells and B-cells. CD19 is found on normal and malignant B-cells, and is known as a reliable marker for B-cells throughout its maturation stages. Anti-CD19 reacts positively with the mantle zone cells, scattered cells, and germinal centers of normal lymph tissues. Although CD20 and CD22 have similar staining patterns to CD19, CD19 is useful because it is also expressed in immature B-cells.
Cluster of Differentiation 19 (CD19) is a surface receptor found on follicular dendritic cells and B-cells. CD19 is found on normal and malignant B-cells, and is known as a reliable marker for B-cells throughout its maturation stages. Anti-CD19 reacts positively with the mantle zone cells, scattered cells, and germinal centers of normal lymph tissues. Although CD20 and CD22 have similar staining patterns to CD19, CD19 is useful because it is also expressed in immature B-cells.
Cluster of Differentiation 19 (CD19) is a surface receptor found on follicular dendritic cells and B-cells. CD19 is found on normal and malignant B-cells, and is known as a reliable marker for B-cells throughout its maturation stages. Anti-CD19 reacts positively with the mantle zone cells, scattered cells, and germinal centers of normal lymph tissues. Although CD20 and CD22 have similar staining patterns to CD19, CD19 is useful because it is also expressed in immature B-cells.
Cluster of Differentiation 19 (CD19) is a surface receptor found on follicular dendritic cells and B-cells. CD19 is found on normal and malignant B-cells, and is known as a reliable marker for B-cells throughout its maturation stages. Anti-CD19 reacts positively with the mantle zone cells, scattered cells, and germinal centers of normal lymph tissues. Although CD20 and CD22 have similar staining patterns to CD19, CD19 is useful because it is also expressed in immature B-cells.
CD1a is part of a heterodimer with β-2-microglobulin, and mediates the capture and presentation of antigens, primarily lipid and glycolipid antigens of self or microbial origin, to T-cells. CD1a is expressed on interdigitating and dermal dendritic cells, veiled cells, Langerhans cells, antigen-presenting cells of the lymph nodes, and cortical thymocytes. Anti-CD1a stains Langerhans cell histiocytosis and cortical T LBL/L pre-T lymphoblastic lymphoma and leukemia. In concert with S100 and CD68, CD1a is very useful for differentiating Rosai-Dorfman disease from other histiocytic diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC530
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Skin, Thymus
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD1a is part of a heterodimer with β-2-microglobulin, and mediates the capture and presentation of antigens, primarily lipid and glycolipid antigens of self or microbial origin, to T-cells. CD1a is expressed on interdigitating and dermal dendritic cells, veiled cells, Langerhans cells, antigen-presenting cells of the lymph nodes, and cortical thymocytes. Anti-CD1a stains Langerhans cell histiocytosis and cortical T LBL/L pre-T lymphoblastic lymphoma and leukemia. In concert with S100 and CD68, CD1a is very useful for differentiating Rosai-Dorfman disease from other histiocytic diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC530
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Skin, Thymus
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD1a is part of a heterodimer with β-2-microglobulin, and mediates the capture and presentation of antigens, primarily lipid and glycolipid antigens of self or microbial origin, to T-cells. CD1a is expressed on interdigitating and dermal dendritic cells, veiled cells, Langerhans cells, antigen-presenting cells of the lymph nodes, and cortical thymocytes. Anti-CD1a stains Langerhans cell histiocytosis and cortical T LBL/L pre-T lymphoblastic lymphoma and leukemia. In concert with S100 and CD68, CD1a is very useful for differentiating Rosai-Dorfman disease from other histiocytic diseases.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD1a is part of a heterodimer with β-2-microglobulin, and mediates the capture and presentation of antigens, primarily lipid and glycolipid antigens of self or microbial origin, to T-cells. CD1a is expressed on interdigitating and dermal dendritic cells, veiled cells, Langerhans cells, antigen-presenting cells of the lymph nodes, and cortical thymocytes. Anti-CD1a stains Langerhans cell histiocytosis and cortical T LBL/L pre-T lymphoblastic lymphoma and leukemia. In concert with S100 and CD68, CD1a is very useful for differentiating Rosai-Dorfman disease from other histiocytic diseases.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC530
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Skin, Thymus
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation (CD20), also known as B-Lymphocyte Antigen, is a non-glycosylated protein expressed on the surface of normal and malignant B-cells, which functions in chemokine signaling and microenvironmental interactions of B-cells. Anti-CD20 stains a minority of Reed-Sternberg cells with Hodgkin's disease. Since CD20 does not stain T-cell malignancies, it is a very useful marker for B-cell lymphomas. CD20 is also not reactive on non-hematopoietic neoplasms.
Cluster of Differentiation (CD20), also known as B-Lymphocyte Antigen, is a non-glycosylated protein expressed on the surface of normal and malignant B-cells, which functions in chemokine signaling and microenvironmental interactions of B-cells. Anti-CD20 stains a minority of Reed-Sternberg cells with Hodgkin's disease. Since CD20 does not stain T-cell malignancies, it is a very useful marker for B-cell lymphomas. CD20 is also not reactive on non-hematopoietic neoplasms.
Cluster of Differentiation (CD20), also known as B-Lymphocyte Antigen, is a non-glycosylated protein expressed on the surface of normal and malignant B-cells, which functions in chemokine signaling and microenvironmental interactions of B-cells. Anti-CD20 stains a minority of Reed-Sternberg cells with Hodgkin's disease. Since CD20 does not stain T-cell malignancies, it is a very useful marker for B-cell lymphomas. CD20 is also not reactive on non-hematopoietic neoplasms.
Cluster of Differentiation (CD20), also known as B-Lymphocyte Antigen, is a non-glycosylated protein expressed on the surface of normal and malignant B-cells, which functions in chemokine signaling and microenvironmental interactions of B-cells. Anti-CD20 stains a minority of Reed-Sternberg cells with Hodgkin's disease. Since CD20 does not stain T-cell malignancies, it is a very useful marker for B-cell lymphomas. CD20 is also not reactive on non-hematopoietic neoplasms.
Cluster of Differentiation 21 (CD21) is a glycoprotein on the surface of B-cells that is bound by Epstein-Barr virus (EBV) during infection of these cells. CD21 staining is useful for recognizing follicular dendritic cell matrices in normal tonsillar and lymph tissue, and can also stain dendritic cell sarcomas. CD21 is also useful for distinguishing marginal zone lymphoma with follicular involvement from follicular lymphoma with marginal zone differentiation. When used in concert with other B- and T-cell markers, CD21 is valuable for differentiating between nodular lymphocyte-predominant Hodgkin's lymphoma, T-cell/histiocyte-rich B-cell lymphoma, and lymphocyte-rich classic Hodgkin's lymphoma. CD21 staining is useful for recognizing abnormal follicular dendritic cell patterns in angioimmunoblastic T-cell lymphoma and follicular T-cell lymphoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC533
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 21 (CD21) is a glycoprotein on the surface of B-cells that is bound by Epstein-Barr virus (EBV) during infection of these cells. CD21 staining is useful for recognizing follicular dendritic cell matrices in normal tonsillar and lymph tissue, and can also stain dendritic cell sarcomas. CD21 is also useful for distinguishing marginal zone lymphoma with follicular involvement from follicular lymphoma with marginal zone differentiation. When used in concert with other B- and T-cell markers, CD21 is valuable for differentiating between nodular lymphocyte-predominant Hodgkin's lymphoma, T-cell/histiocyte-rich B-cell lymphoma, and lymphocyte-rich classic Hodgkin's lymphoma. CD21 staining is useful for recognizing abnormal follicular dendritic cell patterns in angioimmunoblastic T-cell lymphoma and follicular T-cell lymphoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC533
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 21 (CD21) is a glycoprotein on the surface of B-cells that is bound by Epstein-Barr virus (EBV) during infection of these cells. CD21 staining is useful for recognizing follicular dendritic cell matrices in normal tonsillar and lymph tissue, and can also stain dendritic cell sarcomas. CD21 is also useful for distinguishing marginal zone lymphoma with follicular involvement from follicular lymphoma with marginal zone differentiation. When used in concert with other B- and T-cell markers, CD21 is valuable for differentiating between nodular lymphocyte-predominant Hodgkin's lymphoma, T-cell/histiocyte-rich B-cell lymphoma, and lymphocyte-rich classic Hodgkin's lymphoma. CD21 staining is useful for recognizing abnormal follicular dendritic cell patterns in angioimmunoblastic T-cell lymphoma and follicular T-cell lymphoma.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 21 (CD21) is a glycoprotein on the surface of B-cells that is bound by Epstein-Barr virus (EBV) during infection of these cells. CD21 staining is useful for recognizing follicular dendritic cell matrices in normal tonsillar and lymph tissue, and can also stain dendritic cell sarcomas. CD21 is also useful for distinguishing marginal zone lymphoma with follicular involvement from follicular lymphoma with marginal zone differentiation. When used in concert with other B- and T-cell markers, CD21 is valuable for differentiating between nodular lymphocyte-predominant Hodgkin's lymphoma, T-cell/histiocyte-rich B-cell lymphoma, and lymphocyte-rich classic Hodgkin's lymphoma. CD21 staining is useful for recognizing abnormal follicular dendritic cell patterns in angioimmunoblastic T-cell lymphoma and follicular T-cell lymphoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC533
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic mastocytosis and mastocytic leukemia is supported.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC531
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic mastocytosis and mastocytic leukemia is supported.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC531
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic mastocytosis and mastocytic leukemia is supported.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic mastocytosis and mastocytic leukemia is supported.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC531
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
CD317, also known as BST2, tetherin, HM1.2 antigen, DAMP-2, is an integral transmembrane glycoprotein which may play a role in pre-B-cell growth, rheumatoid arthritis, and in antiretroviral defense, that blocks release of retrovirus from the cell surface. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC317
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD317, also known as BST2, tetherin, HM1.2 antigen, DAMP-2, is an integral transmembrane glycoprotein which may play a role in pre-B-cell growth, rheumatoid arthritis, and in antiretroviral defense, that blocks release of retrovirus from the cell surface. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC317
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD317, also known as BST2, tetherin, HM1.2 antigen, DAMP-2, is an integral transmembrane glycoprotein which may play a role in pre-B-cell growth, rheumatoid arthritis, and in antiretroviral defense, that blocks release of retrovirus from the cell surface. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD317, also known as BST2, tetherin, HM1.2 antigen, DAMP-2, is an integral transmembrane glycoprotein which may play a role in pre-B-cell growth, rheumatoid arthritis, and in antiretroviral defense, that blocks release of retrovirus from the cell surface. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC317
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Spleen
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 3 (CD3) is a T-cell co-receptor expressed by T-cells in thymus, peripheral lymphoid tissue, blood, and bone marrow, as well as activated natural killer cells. CD3 is specifically expressed by T-cells at all stages of development including T-cell lymphomas and leukemias; therefore, it can be used to classify T-cell neoplasms from B-cell and myeloid neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC534
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 3 (CD3) is a T-cell co-receptor expressed by T-cells in thymus, peripheral lymphoid tissue, blood, and bone marrow, as well as activated natural killer cells. CD3 is specifically expressed by T-cells at all stages of development including T-cell lymphomas and leukemias; therefore, it can be used to classify T-cell neoplasms from B-cell and myeloid neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC534
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 3 (CD3) is a T-cell co-receptor expressed by T-cells in thymus, peripheral lymphoid tissue, blood, and bone marrow, as well as activated natural killer cells. CD3 is specifically expressed by T-cells at all stages of development including T-cell lymphomas and leukemias; therefore, it can be used to classify T-cell neoplasms from B-cell and myeloid neoplasms.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 3 (CD3) is a T-cell co-receptor expressed by T-cells in thymus, peripheral lymphoid tissue, blood, and bone marrow, as well as activated natural killer cells. CD3 is specifically expressed by T-cells at all stages of development including T-cell lymphomas and leukemias; therefore, it can be used to classify T-cell neoplasms from B-cell and myeloid neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC534
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC044
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC144
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC144
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC044
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC044
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC144
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC145
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node, Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC145
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node, Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC145
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node, Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD45R, also known as MB1, is an isoform of CD45 that is a member of the protein tyrosine phosphatase (PTPase) family. CD45R is expressed specifically on the surface of hematopoietic cells, and has demonstrated function as a regulator of the antigen and cytokine receptor signaling of B- and T-cells. Given that the antigen is located in the membrane of all B-cells, with the exception of plasma cells and some mature T-cells, Anti-CD45R exhibits specific reactivity with most B-lymphocytes. The use of Anti-CD45R is primarily useful in distinguishing B-cell lymphomas from T-cell lymphomas, with specific reactivity to follicle center cells, mantle cells, some medullary thymocytes, and 80% of B-cell lymphomas.
CD45R, also known as MB1, is an isoform of CD45 that is a member of the protein tyrosine phosphatase (PTPase) family. CD45R is expressed specifically on the surface of hematopoietic cells, and has demonstrated function as a regulator of the antigen and cytokine receptor signaling of B- and T-cells. Given that the antigen is located in the membrane of all B-cells, with the exception of plasma cells and some mature T-cells, Anti-CD45R exhibits specific reactivity with most B-lymphocytes. The use of Anti-CD45R is primarily useful in distinguishing B-cell lymphomas from T-cell lymphomas, with specific reactivity to follicle center cells, mantle cells, some medullary thymocytes, and 80% of B-cell lymphomas.
CD45R, also known as MB1, is an isoform of CD45 that is a member of the protein tyrosine phosphatase (PTPase) family. CD45R is expressed specifically on the surface of hematopoietic cells, and has demonstrated function as a regulator of the antigen and cytokine receptor signaling of B- and T-cells. Given that the antigen is located in the membrane of all B-cells, with the exception of plasma cells and some mature T-cells, Anti-CD45R exhibits specific reactivity with most B-lymphocytes. The use of Anti-CD45R is primarily useful in distinguishing B-cell lymphomas from T-cell lymphomas, with specific reactivity to follicle center cells, mantle cells, some medullary thymocytes, and 80% of B-cell lymphomas.
CD45R, also known as MB1, is an isoform of CD45 that is a member of the protein tyrosine phosphatase (PTPase) family. CD45R is expressed specifically on the surface of hematopoietic cells, and has demonstrated function as a regulator of the antigen and cytokine receptor signaling of B- and T-cells. Given that the antigen is located in the membrane of all B-cells, with the exception of plasma cells and some mature T-cells, Anti-CD45R exhibits specific reactivity with most B-lymphocytes. The use of Anti-CD45R is primarily useful in distinguishing B-cell lymphomas from T-cell lymphomas, with specific reactivity to follicle center cells, mantle cells, some medullary thymocytes, and 80% of B-cell lymphomas.
CD45RO is an isoform of CD45 which is expressed in thymocytes, activated T-cells, and subpopulations of resting T-cells. It is a useful marker for T-cell tumours, as Anti-CD45RO demonstrates no reactivity with B-cells. Specifically, CD45RO is implicated in a number of T-cell lymphomas including angioimmunoblastic, lymphoblastic, peripheral, and subcutaneous panniculitis-like T-cell lymphomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC537
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD45RO is an isoform of CD45 which is expressed in thymocytes, activated T-cells, and subpopulations of resting T-cells. It is a useful marker for T-cell tumours, as Anti-CD45RO demonstrates no reactivity with B-cells. Specifically, CD45RO is implicated in a number of T-cell lymphomas including angioimmunoblastic, lymphoblastic, peripheral, and subcutaneous panniculitis-like T-cell lymphomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC537
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD45RO is an isoform of CD45 which is expressed in thymocytes, activated T-cells, and subpopulations of resting T-cells. It is a useful marker for T-cell tumours, as Anti-CD45RO demonstrates no reactivity with B-cells. Specifically, CD45RO is implicated in a number of T-cell lymphomas including angioimmunoblastic, lymphoblastic, peripheral, and subcutaneous panniculitis-like T-cell lymphomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CD45RO is an isoform of CD45 which is expressed in thymocytes, activated T-cells, and subpopulations of resting T-cells. It is a useful marker for T-cell tumours, as Anti-CD45RO demonstrates no reactivity with B-cells. Specifically, CD45RO is implicated in a number of T-cell lymphomas including angioimmunoblastic, lymphoblastic, peripheral, and subcutaneous panniculitis-like T-cell lymphomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC537
Antibody Isotype:
IgG2a
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 4 (CD4) is a membrane glycoprotein expressed in T helper cells, monocytes, macrophages, granulocytes, and dendritic cells, and is a receptor of human immunodeficiency virus (HIV). CD4 staining is used for identifying lymphoproliferative disorders. Since the majority of peripheral T-cell lymphomas arise from the T helper cell subset, CD4 expression can be found in most forms of T-cell lymphomas as well as anaplastic large T-cell lymphomas and mycosis fungoides. Since CD4 may be aberrantly expressed in neoplastic T-lymphocytes, a panel of markers may be used to identify such tumours. CD4(+) CD25(+) T-cells are reported to exert immunosuppression, which is commonly observed in various types of cancers, including non-small cell lung cancer and cancers of the breast, prostate, and ovary.
Cluster of Differentiation 4 (CD4) is a membrane glycoprotein expressed in T helper cells, monocytes, macrophages, granulocytes, and dendritic cells, and is a receptor of human immunodeficiency virus (HIV). CD4 staining is used for identifying lymphoproliferative disorders. Since the majority of peripheral T-cell lymphomas arise from the T helper cell subset, CD4 expression can be found in most forms of T-cell lymphomas as well as anaplastic large T-cell lymphomas and mycosis fungoides. Since CD4 may be aberrantly expressed in neoplastic T-lymphocytes, a panel of markers may be used to identify such tumours. CD4(+) CD25(+) T-cells are reported to exert immunosuppression, which is commonly observed in various types of cancers, including non-small cell lung cancer and cancers of the breast, prostate, and ovary.
Cluster of Differentiation 4 (CD4) is a membrane glycoprotein expressed in T helper cells, monocytes, macrophages, granulocytes, and dendritic cells, and is a receptor of human immunodeficiency virus (HIV). CD4 staining is used for identifying lymphoproliferative disorders. Since the majority of peripheral T-cell lymphomas arise from the T helper cell subset, CD4 expression can be found in most forms of T-cell lymphomas as well as anaplastic large T-cell lymphomas and mycosis fungoides. Since CD4 may be aberrantly expressed in neoplastic T-lymphocytes, a panel of markers may be used to identify such tumours. CD4(+) CD25(+) T-cells are reported to exert immunosuppression, which is commonly observed in various types of cancers, including non-small cell lung cancer and cancers of the breast, prostate, and ovary.
Cluster of Differentiation 4 (CD4) is a membrane glycoprotein expressed in T helper cells, monocytes, macrophages, granulocytes, and dendritic cells, and is a receptor of human immunodeficiency virus (HIV). CD4 staining is used for identifying lymphoproliferative disorders. Since the majority of peripheral T-cell lymphomas arise from the T helper cell subset, CD4 expression can be found in most forms of T-cell lymphomas as well as anaplastic large T-cell lymphomas and mycosis fungoides. Since CD4 may be aberrantly expressed in neoplastic T-lymphocytes, a panel of markers may be used to identify such tumours. CD4(+) CD25(+) T-cells are reported to exert immunosuppression, which is commonly observed in various types of cancers, including non-small cell lung cancer and cancers of the breast, prostate, and ovary.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 57 (CD57), also known as NK-1, is an antigen detectable in natural killer cells, some T-lymphocytes and normal peripheral blood mononuclear cells, myeloid cells, and a variety of polypeptides, lipids, and chondroitin sulfate proteoglycans. CD57 is indicated as a marker for tumours of neuroendocrine origin, including pheochromocytomas, paragangliomas, medulloblastomas, and carcinoid tumour, as well as various neural tumours including neuromas, neurofibromas, schwannomas, and granular cell tumours. CD57 is also detectable in ganglioneuroma and prostate carcinoma. Anti-CD57 is used to distinguish nodular lymphocyte-predominant Hodgkin's lymphoma from T-cell/histiocyte-rich large B-cell lymphoma, nodular sclerosis Hodgkin's disease, and follicular lymphoma.
Cluster of Differentiation 57 (CD57), also known as NK-1, is an antigen detectable in natural killer cells, some T-lymphocytes and normal peripheral blood mononuclear cells, myeloid cells, and a variety of polypeptides, lipids, and chondroitin sulfate proteoglycans. CD57 is indicated as a marker for tumours of neuroendocrine origin, including pheochromocytomas, paragangliomas, medulloblastomas, and carcinoid tumour, as well as various neural tumours including neuromas, neurofibromas, schwannomas, and granular cell tumours. CD57 is also detectable in ganglioneuroma and prostate carcinoma. Anti-CD57 is used to distinguish nodular lymphocyte-predominant Hodgkin's lymphoma from T-cell/histiocyte-rich large B-cell lymphoma, nodular sclerosis Hodgkin's disease, and follicular lymphoma.
Cluster of Differentiation 57 (CD57), also known as NK-1, is an antigen detectable in natural killer cells, some T-lymphocytes and normal peripheral blood mononuclear cells, myeloid cells, and a variety of polypeptides, lipids, and chondroitin sulfate proteoglycans. CD57 is indicated as a marker for tumours of neuroendocrine origin, including pheochromocytomas, paragangliomas, medulloblastomas, and carcinoid tumour, as well as various neural tumours including neuromas, neurofibromas, schwannomas, and granular cell tumours. CD57 is also detectable in ganglioneuroma and prostate carcinoma. Anti-CD57 is used to distinguish nodular lymphocyte-predominant Hodgkin's lymphoma from T-cell/histiocyte-rich large B-cell lymphoma, nodular sclerosis Hodgkin's disease, and follicular lymphoma.
Cluster of Differentiation 57 (CD57), also known as NK-1, is an antigen detectable in natural killer cells, some T-lymphocytes and normal peripheral blood mononuclear cells, myeloid cells, and a variety of polypeptides, lipids, and chondroitin sulfate proteoglycans. CD57 is indicated as a marker for tumours of neuroendocrine origin, including pheochromocytomas, paragangliomas, medulloblastomas, and carcinoid tumour, as well as various neural tumours including neuromas, neurofibromas, schwannomas, and granular cell tumours. CD57 is also detectable in ganglioneuroma and prostate carcinoma. Anti-CD57 is used to distinguish nodular lymphocyte-predominant Hodgkin's lymphoma from T-cell/histiocyte-rich large B-cell lymphoma, nodular sclerosis Hodgkin's disease, and follicular lymphoma.
Cluster of Differentiation 5 (CD5) is expressed in high levels on the surface of T-cells, while the expression levels and role of CD5 in B-cells is not well documented. As a part of a diagnostic panel, its utility lies predominantly as a marker for T-cells, with over 70% of T-cell neoplasms expressing CD5. In particular, it is correlated with chronic lymphocytic leukemia and small lymphocytic lymphomas, mantle cell lymphoma, as well as a subset of diffuse large B-cell lymphomas. CD5 demonstrates positive expression in thymic carcinomas, and is not as sensitive as CD3. CD5 also has value as a prognostic indicator, as it is associated with poor prognosis in acute T-cell lymphoblastic leukemia.
Cluster of Differentiation 5 (CD5) is expressed in high levels on the surface of T-cells, while the expression levels and role of CD5 in B-cells is not well documented. As a part of a diagnostic panel, its utility lies predominantly as a marker for T-cells, with over 70% of T-cell neoplasms expressing CD5. In particular, it is correlated with chronic lymphocytic leukemia and small lymphocytic lymphomas, mantle cell lymphoma, as well as a subset of diffuse large B-cell lymphomas. CD5 demonstrates positive expression in thymic carcinomas, and is not as sensitive as CD3. CD5 also has value as a prognostic indicator, as it is associated with poor prognosis in acute T-cell lymphoblastic leukemia.
Cluster of Differentiation 5 (CD5) is expressed in high levels on the surface of T-cells, while the expression levels and role of CD5 in B-cells is not well documented. As a part of a diagnostic panel, its utility lies predominantly as a marker for T-cells, with over 70% of T-cell neoplasms expressing CD5. In particular, it is correlated with chronic lymphocytic leukemia and small lymphocytic lymphomas, mantle cell lymphoma, as well as a subset of diffuse large B-cell lymphomas. CD5 demonstrates positive expression in thymic carcinomas, and is not as sensitive as CD3. CD5 also has value as a prognostic indicator, as it is associated with poor prognosis in acute T-cell lymphoblastic leukemia.
Cluster of Differentiation 5 (CD5) is expressed in high levels on the surface of T-cells, while the expression levels and role of CD5 in B-cells is not well documented. As a part of a diagnostic panel, its utility lies predominantly as a marker for T-cells, with over 70% of T-cell neoplasms expressing CD5. In particular, it is correlated with chronic lymphocytic leukemia and small lymphocytic lymphomas, mantle cell lymphoma, as well as a subset of diffuse large B-cell lymphomas. CD5 demonstrates positive expression in thymic carcinomas, and is not as sensitive as CD3. CD5 also has value as a prognostic indicator, as it is associated with poor prognosis in acute T-cell lymphoblastic leukemia.
Cluster of Differentiation 5 (CD5) is expressed in high levels on the surface of T-cells, while the expression levels and role of CD5 in B-cells is not well documented. As a part of a diagnostic panel, its utility lies predominantly as a marker for T-cells, with over 70% of T-cell neoplasms expressing CD5. In particular, it is correlated with chronic lymphocytic leukemia and small lymphocytic lymphomas, mantle cell lymphoma, as well as a subset of diffuse large B-cell lymphomas. CD5 demonstrates positive expression in thymic carcinomas, and is not as sensitive as CD3. CD5 also has value as a prognostic indicator, as it is associated with poor prognosis in acute T-cell lymphoblastic leukemia.
Cluster of Differentiation 5 (CD5) is expressed in high levels on the surface of T-cells, while the expression levels and role of CD5 in B-cells is not well documented. As a part of a diagnostic panel, its utility lies predominantly as a marker for T-cells, with over 70% of T-cell neoplasms expressing CD5. In particular, it is correlated with chronic lymphocytic leukemia and small lymphocytic lymphomas, mantle cell lymphoma, as well as a subset of diffuse large B-cell lymphomas. CD5 demonstrates positive expression in thymic carcinomas, and is not as sensitive as CD3. CD5 also has value as a prognostic indicator, as it is associated with poor prognosis in acute T-cell lymphoblastic leukemia.
Cluster of Differentiation 5 (CD5) is expressed in high levels on the surface of T-cells, while the expression levels and role of CD5 in B-cells is not well documented. As a part of a diagnostic panel, its utility lies predominantly as a marker for T-cells, with over 70% of T-cell neoplasms expressing CD5. In particular, it is correlated with chronic lymphocytic leukemia and small lymphocytic lymphomas, mantle cell lymphoma, as well as a subset of diffuse large B-cell lymphomas. CD5 demonstrates positive expression in thymic carcinomas, and is not as sensitive as CD3. CD5 also has value as a prognostic indicator, as it is associated with poor prognosis in acute T-cell lymphoblastic leukemia.
Cluster of Differentiation 5 (CD5) is expressed in high levels on the surface of T-cells, while the expression levels and role of CD5 in B-cells is not well documented. As a part of a diagnostic panel, its utility lies predominantly as a marker for T-cells, with over 70% of T-cell neoplasms expressing CD5. In particular, it is correlated with chronic lymphocytic leukemia and small lymphocytic lymphomas, mantle cell lymphoma, as well as a subset of diffuse large B-cell lymphomas. CD5 demonstrates positive expression in thymic carcinomas, and is not as sensitive as CD3. CD5 also has value as a prognostic indicator, as it is associated with poor prognosis in acute T-cell lymphoblastic leukemia.
Cluster of Differentiation 61 (CD61), also known as Glycoprotein IIIa or GPIIIa, is an antigen expressed on megakaryocytes, platelets, myeloid cells, monocytes, endothelial cells, smooth muscle cells, and macrophages. It is involved in platelet aggregation and acts as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin. Anti-CD61 is used for identifying megakaryocytopoiesis, as seen in megakaryoblastic leukemias, myelodysplastic disorders, and acute myeloid leukemias. CD61 is also indicated as a marker for platelet adhesion in advanced atherosclerosis and has been reported in the identification of fat embolism in pulmonary tissue.
Cluster of Differentiation 61 (CD61), also known as Glycoprotein IIIa or GPIIIa, is an antigen expressed on megakaryocytes, platelets, myeloid cells, monocytes, endothelial cells, smooth muscle cells, and macrophages. It is involved in platelet aggregation and acts as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin. Anti-CD61 is used for identifying megakaryocytopoiesis, as seen in megakaryoblastic leukemias, myelodysplastic disorders, and acute myeloid leukemias. CD61 is also indicated as a marker for platelet adhesion in advanced atherosclerosis and has been reported in the identification of fat embolism in pulmonary tissue.
Cluster of Differentiation 61 (CD61), also known as Glycoprotein IIIa or GPIIIa, is an antigen expressed on megakaryocytes, platelets, myeloid cells, monocytes, endothelial cells, smooth muscle cells, and macrophages. It is involved in platelet aggregation and acts as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin. Anti-CD61 is used for identifying megakaryocytopoiesis, as seen in megakaryoblastic leukemias, myelodysplastic disorders, and acute myeloid leukemias. CD61 is also indicated as a marker for platelet adhesion in advanced atherosclerosis and has been reported in the identification of fat embolism in pulmonary tissue.
Cluster of Differentiation 61 (CD61), also known as Glycoprotein IIIa or GPIIIa, is an antigen expressed on megakaryocytes, platelets, myeloid cells, monocytes, endothelial cells, smooth muscle cells, and macrophages. It is involved in platelet aggregation and acts as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin. Anti-CD61 is used for identifying megakaryocytopoiesis, as seen in megakaryoblastic leukemias, myelodysplastic disorders, and acute myeloid leukemias. CD61 is also indicated as a marker for platelet adhesion in advanced atherosclerosis and has been reported in the identification of fat embolism in pulmonary tissue.
Cluster of Differentiation 63 (CD63) is a lysosomal membrane glycoprotein identified as a platelet activation molecule. CD63 localizes to the membrane and cytoplasm of many cell types including lymphoid, myeloid, and endothelial cells. CD63 is a useful marker for malignant melanoma, and for distinguishing between renal oncocytoma and eosinophilic renal cell carcinoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC540
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 63 (CD63) is a lysosomal membrane glycoprotein identified as a platelet activation molecule. CD63 localizes to the membrane and cytoplasm of many cell types including lymphoid, myeloid, and endothelial cells. CD63 is a useful marker for malignant melanoma, and for distinguishing between renal oncocytoma and eosinophilic renal cell carcinoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC540
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 63 (CD63) is a lysosomal membrane glycoprotein identified as a platelet activation molecule. CD63 localizes to the membrane and cytoplasm of many cell types including lymphoid, myeloid, and endothelial cells. CD63 is a useful marker for malignant melanoma, and for distinguishing between renal oncocytoma and eosinophilic renal cell carcinoma.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 63 (CD63) is a lysosomal membrane glycoprotein identified as a platelet activation molecule. CD63 localizes to the membrane and cytoplasm of many cell types including lymphoid, myeloid, and endothelial cells. CD63 is a useful marker for malignant melanoma, and for distinguishing between renal oncocytoma and eosinophilic renal cell carcinoma.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC540
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 68 (CD68) is a heavily glycosylated transmembrane antigen that is detected in lysosomes, tissue macrophages, Langerhans cells, dendritic cells, monocytes, Kupffer cells, osteoclasts, and granulocytes. Anti-CD68 may be useful in identifying myelomonocytic and histiocytic tumours, and for differentiating between malignant fibrous histiocytoma and other pleomorphic sarcomas. However, other lysosome-rich cells may also stain, since Anti-CD68 detects a formalin-resistant epitope that may be associated with lysosomal granules.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC068
Antibody Isotype:
IgG3
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 68 (CD68) is a heavily glycosylated transmembrane antigen that is detected in lysosomes, tissue macrophages, Langerhans cells, dendritic cells, monocytes, Kupffer cells, osteoclasts, and granulocytes. Anti-CD68 may be useful in identifying myelomonocytic and histiocytic tumours, and for differentiating between malignant fibrous histiocytoma and other pleomorphic sarcomas. However, other lysosome-rich cells may also stain, since Anti-CD68 detects a formalin-resistant epitope that may be associated with lysosomal granules.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC068
Antibody Isotype:
IgG3
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 68 (CD68) is a heavily glycosylated transmembrane antigen that is detected in lysosomes, tissue macrophages, Langerhans cells, dendritic cells, monocytes, Kupffer cells, osteoclasts, and granulocytes. Anti-CD68 may be useful in identifying myelomonocytic and histiocytic tumours, and for differentiating between malignant fibrous histiocytoma and other pleomorphic sarcomas. However, other lysosome-rich cells may also stain, since Anti-CD68 detects a formalin-resistant epitope that may be associated with lysosomal granules.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 68 (CD68) is a heavily glycosylated transmembrane antigen that is detected in lysosomes, tissue macrophages, Langerhans cells, dendritic cells, monocytes, Kupffer cells, osteoclasts, and granulocytes. Anti-CD68 may be useful in identifying myelomonocytic and histiocytic tumours, and for differentiating between malignant fibrous histiocytoma and other pleomorphic sarcomas. However, other lysosome-rich cells may also stain, since Anti-CD68 detects a formalin-resistant epitope that may be associated with lysosomal granules.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC068
Antibody Isotype:
IgG3
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 71 (CD71), also known as Transferrin Receptor Protein 1 (TfR1) or the transferrin receptor, is a cell surface proliferation marker that is involved in the cellular uptake of iron. CD71 is most highly expressed in early erythroid precursors and is fully absent from mature erythrocytes; CD71 is therefore highly useful as a marker for erythroid components within bone marrow biopsy specimens, without interference from mature erythrocytes. CD71 expression has been indicated in invasive breast carcinoma with acquired resistance to tamoxifen, and has been linked to poor prognosis in ER+/luminal-like breast cancer. Anti-CD71 is used in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC071
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Bone Marrow
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 71 (CD71), also known as Transferrin Receptor Protein 1 (TfR1) or the transferrin receptor, is a cell surface proliferation marker that is involved in the cellular uptake of iron. CD71 is most highly expressed in early erythroid precursors and is fully absent from mature erythrocytes; CD71 is therefore highly useful as a marker for erythroid components within bone marrow biopsy specimens, without interference from mature erythrocytes. CD71 expression has been indicated in invasive breast carcinoma with acquired resistance to tamoxifen, and has been linked to poor prognosis in ER+/luminal-like breast cancer. Anti-CD71 is used in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC071
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Bone Marrow
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 71 (CD71), also known as Transferrin Receptor Protein 1 (TfR1) or the transferrin receptor, is a cell surface proliferation marker that is involved in the cellular uptake of iron. CD71 is most highly expressed in early erythroid precursors and is fully absent from mature erythrocytes; CD71 is therefore highly useful as a marker for erythroid components within bone marrow biopsy specimens, without interference from mature erythrocytes. CD71 expression has been indicated in invasive breast carcinoma with acquired resistance to tamoxifen, and has been linked to poor prognosis in ER+/luminal-like breast cancer. Anti-CD71 is used in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 71 (CD71), also known as Transferrin Receptor Protein 1 (TfR1) or the transferrin receptor, is a cell surface proliferation marker that is involved in the cellular uptake of iron. CD71 is most highly expressed in early erythroid precursors and is fully absent from mature erythrocytes; CD71 is therefore highly useful as a marker for erythroid components within bone marrow biopsy specimens, without interference from mature erythrocytes. CD71 expression has been indicated in invasive breast carcinoma with acquired resistance to tamoxifen, and has been linked to poor prognosis in ER+/luminal-like breast cancer. Anti-CD71 is used in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC071
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Bone Marrow
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 73 (CD73), also known as Ecto-5'-Nucleotidase (ecto-5'-NT), is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells <em>in vitro</em>, as well as tumour angiogenesis and tumour immune escape <em>in vivo</em>. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma.
Cluster of Differentiation 73 (CD73), also known as Ecto-5'-Nucleotidase (ecto-5'-NT), is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells <em>in vitro</em>, as well as tumour angiogenesis and tumour immune escape <em>in vivo</em>. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma.
Cluster of Differentiation 73 (CD73), also known as Ecto-5'-Nucleotidase (ecto-5'-NT), is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells <em>in vitro</em>, as well as tumour angiogenesis and tumour immune escape <em>in vivo</em>. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma.
Cluster of Differentiation 73 (CD73), also known as Ecto-5'-Nucleotidase (ecto-5'-NT), is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells <em>in vitro</em>, as well as tumour angiogenesis and tumour immune escape <em>in vivo</em>. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma.
Cluster of Differentiation 79a (CD79a) is a molecule that dimerizes with CD79b to form the B-cell antigen receptor complex that enables antigen presentation. CD79a is specifically expressed in B lineage cell lines including early progenitors, pre-B and mature B-cell lines, normal resting B-lymphocytes, and polyclonally activated B-cell blasts. Since Anti-CD79a and Anti-CD20 both react positively with lymphomas in many of the same cases, Anti-CD79a is frequently used in conjunction with Anti-CD20. In comparison to CD20, CD79a has a greater likelihood of staining plasma cell myeloma and some endothelia. CD79a also frequently stains acute promyelocytic leukemia (FAB-M3), but infrequently stains other types of myeloid leukemia.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC079
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 79a (CD79a) is a molecule that dimerizes with CD79b to form the B-cell antigen receptor complex that enables antigen presentation. CD79a is specifically expressed in B lineage cell lines including early progenitors, pre-B and mature B-cell lines, normal resting B-lymphocytes, and polyclonally activated B-cell blasts. Since Anti-CD79a and Anti-CD20 both react positively with lymphomas in many of the same cases, Anti-CD79a is frequently used in conjunction with Anti-CD20. In comparison to CD20, CD79a has a greater likelihood of staining plasma cell myeloma and some endothelia. CD79a also frequently stains acute promyelocytic leukemia (FAB-M3), but infrequently stains other types of myeloid leukemia.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC079
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 79a (CD79a) is a molecule that dimerizes with CD79b to form the B-cell antigen receptor complex that enables antigen presentation. CD79a is specifically expressed in B lineage cell lines including early progenitors, pre-B and mature B-cell lines, normal resting B-lymphocytes, and polyclonally activated B-cell blasts. Since Anti-CD79a and Anti-CD20 both react positively with lymphomas in many of the same cases, Anti-CD79a is frequently used in conjunction with Anti-CD20. In comparison to CD20, CD79a has a greater likelihood of staining plasma cell myeloma and some endothelia. CD79a also frequently stains acute promyelocytic leukemia (FAB-M3), but infrequently stains other types of myeloid leukemia.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 79a (CD79a) is a molecule that dimerizes with CD79b to form the B-cell antigen receptor complex that enables antigen presentation. CD79a is specifically expressed in B lineage cell lines including early progenitors, pre-B and mature B-cell lines, normal resting B-lymphocytes, and polyclonally activated B-cell blasts. Since Anti-CD79a and Anti-CD20 both react positively with lymphomas in many of the same cases, Anti-CD79a is frequently used in conjunction with Anti-CD20. In comparison to CD20, CD79a has a greater likelihood of staining plasma cell myeloma and some endothelia. CD79a also frequently stains acute promyelocytic leukemia (FAB-M3), but infrequently stains other types of myeloid leukemia.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC079
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 8 (CD8) is a transmembrane glycoprotein that serves as a co-receptor for the T-cell receptor. It is expressed in cytotoxic T-cells, natural killer cells, cortical thymocytes, some null cells, and bone marrow cells. Anti-CD8, in a panel of other antibodies, may be used to differentiate between reactive and neoplastic T-lymphocytes.
Cluster of Differentiation 8 (CD8) is a transmembrane glycoprotein that serves as a co-receptor for the T-cell receptor. It is expressed in cytotoxic T-cells, natural killer cells, cortical thymocytes, some null cells, and bone marrow cells. Anti-CD8, in a panel of other antibodies, may be used to differentiate between reactive and neoplastic T-lymphocytes.
Cluster of Differentiation 8 (CD8) is a transmembrane glycoprotein that serves as a co-receptor for the T-cell receptor. It is expressed in cytotoxic T-cells, natural killer cells, cortical thymocytes, some null cells, and bone marrow cells. Anti-CD8, in a panel of other antibodies, may be used to differentiate between reactive and neoplastic T-lymphocytes.
Cluster of Differentiation 8 (CD8) is a transmembrane glycoprotein that serves as a co-receptor for the T-cell receptor. It is expressed in cytotoxic T-cells, natural killer cells, cortical thymocytes, some null cells, and bone marrow cells. Anti-CD8, in a panel of other antibodies, may be used to differentiate between reactive and neoplastic T-lymphocytes.
Cluster of Differentiation 99 (CD99) is a glycosylated transmembrane protein expressed by lymphocytes, cortical thymocytes, granulosa cells of the ovary, pancreatic islet cells, Sertoli cells, and endothelial cells. CD99 produces diffuse membrane staining patterns on nearly all Ewing's sarcoma and primitive peripheral neuroectodermal tumours. CD99 may be found in synovial sarcoma, neuroendocrine carcinoma, acute myeloid leukemia, mesenchymal chondrosarcoma, lymphoblastic lymphoma, small round blue cell tumours, solitary fibrous tumours, vascular tumours, and myeloid sarcoma. It produces heterogeneous staining patterns which must be accompanied by other antibody staining for a final diagnosis.
